DELAWARE — The boardroom battle at digital mortgage pioneer Better Home & Finance Holding Co. has officially escalated from a high-stakes corporate coup into an all-out legal war.
Vishal Garg, the embattled founder and former CEO of the company, has filed a sweeping lawsuit in the Delaware Court of Chancery against Better, interim CEO Daniel Lewis, and six fellow members of the board of directors. The legal action accuses the leadership team of executing a premeditated boardroom coup, unlawfully entrenching themselves, and deploying a draconian "poison pill" defense strategy specifically engineered to strip shareholders of their fundamental voting rights.
The complaint introduces three core legal counts—including breach of fiduciary duty and two claims for declaratory judgment—asking the Delaware court to invalidate the board’s newly formed special committee and dismantle its shareholder rights plan.
The courtroom showdown is the latest and most explosive development in an ongoing saga that has paralyzed Better’s leadership structure, wiped out significant market value, and triggered a fierce proxy war between the company’s founder and its institutional board members.
Main Facts of the Legal Battle
At the heart of the Delaware litigation is a struggle for absolute control of Better Home & Finance Holding Co.
According to court filings, the conflict was ignited in late July when activist hedge fund manager Daniel Lewis—founder of Orange Capital—engineered his appointment to Better’s board. Within days of securing his seat, Lewis allegedly orchestrated a coordinated effort that culminated in Garg’s abrupt termination as chief executive officer without notice or cause.
In response to his ouster, Garg has launched a multi-front legal counter-offensive. His Delaware Chancery Court complaint targets what he characterizes as an entrenched, self-serving board of directors that allegedly utilized corporate machinery—most notably a 15% trigger "poison pill" and a specially convened governance committee—to block shareholders from restoring him to power.
Furthermore, the legal fallout extends beyond Delaware. The battle encompasses a concurrent federal lawsuit filed by Better against Garg in the U.S. District Court for the Southern District of New York, where the company accuses the founder of unlawful solicitation and disclosure violations during his attempts to rally a voting majority.
Key elements of Garg’s Delaware complaint include:
- Breach of Fiduciary Duties: Allegations that interim CEO Daniel Lewis and allied board members acted in their own self-interest rather than the financial well-being of the company and its shareholders.
- The "Poison Pill" Challenge: A direct challenge to the board’s August 20 adoption of a shareholder rights plan containing a 15% ownership threshold, designed to dilute potential insurgent blocks.
- Voter Suppression Claims: Assertions that vague provisions within the poison pill—specifically regarding "agreements, arrangements, or understandings" among shareholders—are intentionally designed to chill communication and prevent cooperative voting blocs.
Chronology of the Corporate Coup
To fully understand how Better Home & Finance transitioned from a publicly traded fintech innovator to a battleground of competing lawsuits, one must examine the rapid timeline of events that unfolded across July and August.
July 27: The Influx of Activism
According to the Delaware complaint, Daniel Lewis utilized "lies and manipulation" to maneuver his way onto Better’s board of directors. Described as an activist hedge fund manager and the founder of Orange Capital, Lewis quickly consolidated influence among fellow directors.
August 3: The Abrupt Ouster
Just one week after securing his board seat, Lewis convinced the governing body to terminate Vishal Garg as CEO. The firing was executed without prior notice or official cause, catching institutional investors and market watchers off guard.
Mid-August: Golden Handshakes and Counter-Offers
Following his termination, Better’s leadership attempted to appease the founder by offering him an elevated advisory role. The proposed package included a position as vice chairman and advisor to the CEO, featuring an annual cash component of $750,000 alongside an equity award of 875,000 shares. Valued at more than $15 million over a 16-month timeframe, Garg ultimately rejected the offer, citing its limited scope and reduced operational responsibility.
On August 7, two directors allegedly approached Garg with a backchannel compromise: if Garg could definitively prove he held 50.1% stockholder support, those two directors—alongside two others—would resign, handing Garg two board seats and allowing him to oust Lewis.
The Math Error and Federal Retaliation
Motivated by the proposal, Garg set out to secure written consents from major shareholders. However, an administrative error based on foundational data provided directly by the company resulted in an overstatement of his support. While Garg claimed to have secured 51.65% of the voting power, his actual holdings sat at roughly 45%.
Sensing vulnerability, Better struck back. On August 18, the company filed a federal lawsuit in the Southern District of New York alleging that Garg had engaged in unlawful proxy solicitation and federal disclosure violations.
August 20: The Special Committee and the Poison Pill
Capitalizing on the proxy controversy, an exclusive special committee of the board—from which Garg was entirely excluded—moved swiftly. On August 20, the committee adopted a classic shareholder rights plan, commonly known as a poison pill, with a 15% ownership trigger designed to take effect on August 31.
August 26–27: Legal Escalation
On Tuesday, Garg officially filed his opposition to Better’s motion for a preliminary injunction and temporary restraining order in the New York federal court, dismissing the company’s claims as "without merit." Simultaneously, Garg filed his comprehensive lawsuit in the Delaware Court of Chancery, setting the stage for a landmark corporate governance showdown.
Supporting Data and Financial Fallout
The boardroom turbulence at Better has not occurred in a vacuum; it has inflicted severe collateral damage on the company’s market valuation and investor confidence.
- 60% Stock Plunge: According to financial disclosures cited in the Delaware complaint, Better’s stock price has plummeted by nearly 60% since Garg was stripped of his executive duties. The drastic market correction reflects deep investor anxiety over executive instability and strategic direction.
- Institutional Rebuilding Efforts: Large institutional stockholders have reportedly rebelled against the board’s maneuvers, actively demanding Garg’s reinstatement to stabilize operations and recover lost equity value.
- The $15 Million Package: The financial magnitude of Better’s attempt to sideline Garg is underscored by the rejected compensation package—$750,000 per year in cash and 875,000 shares valued upwards of $15 million.
- The 15% Poison Pill Trigger: The shareholder rights plan established by the special committee sets an aggressive 15% beneficial ownership ceiling, making it mathematically hazardous for any unapproved investor group to consolidate voting power without triggering massive share dilution.
- The 45% vs. 51.65% Discrepancy: The margin of error in Garg’s initial consent count—overstating support by roughly 6.65 percentage points based on flawed internal corporate data—serves as the central factual dispute in the federal litigation.
Official Responses and Stakeholder Perspectives
As of Wednesday, official commentary from the company’s corporate communications department has been notably sparse. A spokesperson for Better did not immediately reply to multiple requests for comment submitted by HousingWire.
However, court documents filed by both legal teams provide deep insight into their respective defensive postures.
Vishal Garg’s Legal Stance
Through his legal counsel in the Delaware Court of Chancery, Garg argues that the current board is operating in bad faith, prioritizing self-preservation and entrenchment over fiduciary accountability to shareholders.
Regarding the poison pill, Garg’s legal team launched a blistering critique against its sweeping provisions. The lawsuit highlights a notoriously vague clause that aggregates the shares of any investor deemed to have an undefined "agreement, arrangement or understanding (whether or not in writing)." Garg argues this language acts as a chilling effect, effectively criminalizing ordinary communication among concerned stockholders seeking to coordinate their voting strategies. Furthermore, the complaint condemns the board’s retention of "sole discretion" to selectively waive violations of the pill as a blatant tool for selective enforcement and voter suppression.
In the federal arena, Garg’s opposition to the New York preliminary injunction maintains that his outreach to shareholders did not constitute illegal solicitation, framing the company’s federal lawsuit as a retaliatory weapon designed to silence valid stockholder dissent.
The Board and Management’s Position
Conversely, interim CEO Daniel Lewis and the Better board maintain that their actions are entirely lawful and necessary to protect the corporation from improper, coercive takeover tactics.
In their New York federal complaint, company representatives argue that Garg’s hurried attempts to retake control relied on inaccurate representations, improper communications, and violations of federal disclosure rules. By establishing the special committee and implementing the poison pill, the board asserts it is fulfilling its fiduciary duty to shield all public shareholders from a disorganized, potentially non-compliant shift in corporate governance.
Broader Implications for FinTech and Corporate Governance
The high-stakes legal battle playing out between Vishal Garg and Better Home & Finance holds profound implications that extend far beyond the mortgage technology sector.
1. The Limits of Founder Power in Public Companies
The saga serves as a cautionary tale regarding the transition of high-growth startups into publicly traded entities. Founders who retain outsized operational influence often find themselves vulnerable once institutional investors and activist hedge fund managers—such as Orange Capital’s Daniel Lewis—gain a foothold in the boardroom. The outcome of the Delaware litigation may set a precedent for how much leverage founders retain when clashing with activist-led boards.
2. Scrutiny of Defensive "Poison Pills"
By challenging the board’s poison pill in the Delaware Court of Chancery—the nation’s premier arbiter of corporate law—Garg has placed modern defensive mechanisms under judicial microscope. If the court finds that the 15% trigger and its vague "agreement or understanding" clauses were implemented primarily for entrenchment rather than shareholder protection, it could signal a higher legal bar for boards attempting to block activist or founder-led proxy challenges.
3. Market Confidence and Shareholder Activism
With Better’s stock down nearly 60% since the leadership shakeup, the case highlights the destructive nature of prolonged governance disputes on public market valuations. Institutional investors watching from the sidelines are increasingly vocal about the need for corporate stability, proving that executive turf wars invariably extract a heavy toll on retail and institutional shareholders alike.
As the Delaware Court of Chancery reviews the merit of Garg’s three-count complaint, and as the federal court in New York weighs the preliminary injunction, the future of Better Home & Finance hangs in the balance. Whether the company will be steered by its founding visionary or governed by an activist-led board remains one of the most closely watched corporate governance battles of the decade.
